Equities researchers at Goldman Sachs Group began coverage on shares of EXACT Sciences (NASDAQ:EXAS) in a report released on Monday, Marketbeat Ratings reports. The firm set a “neutral” rating and a $51.00 price target on the medical research company’s stock. Goldman Sachs Group’s price target suggests a potential upside of 2.33% from the stock’s previous close.
EXAS has been the subject of a number of other reports. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a report on Tuesday, January 16th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. Canaccord Genuity reissued a “buy” rating and issued a $60.00 target price (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Finally, Robert W. Baird reissued a “buy” rating and issued a $49.00 target price on shares of EXACT Sciences in a report on Friday, October 6th. Eight equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of “Buy” and a consensus price target of $52.84.
EXACT Sciences (EXAS) traded down $0.23 during mid-day trading on Monday, hitting $49.84. 1,951,663 shares of the company were exchanged, compared to its average volume of 3,958,540. EXACT Sciences has a 1 year low of $17.77 and a 1 year high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of -43.34 and a beta of 0.68.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Krilogy Financial LLC lifted its position in shares of EXACT Sciences by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the last quarter. Crow Point Partners LLC bought a new stake in shares of EXACT Sciences during the fourth quarter worth $145,000. Oppenheimer Asset Management Inc. lifted its position in shares of EXACT Sciences by 2,925.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of EXACT Sciences during the third quarter worth $183,000. Finally, Crescent Grove Advisors LLC bought a new stake in shares of EXACT Sciences during the third quarter worth $200,000. Institutional investors own 82.02% of the company’s stock.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.